Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

<p>Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics BDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024 BDTX-1535 Phase 1 dose escalation data in GBM expected later […]</p>
<p>The post <a href="https://forextv.com/top-news/black-diamond-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-update/">Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>